Related Experiment Videos
Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary
M Masotti1, A Turá, C Crexells
1Sant Pau Investigation Foundation, Barcelona, Spain.
Insights
Antiplatelet therapy significantly improved percutaneous transluminal coronary angioplasty (PTCA) success rates, reducing severe complications. Peri-angioplasty antiplatelet use is crucial for preventing adverse events during PTCA.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) is a common procedure for coronary artery disease.
- A sudden, unexpected drop in PTCA success rates was observed.
- The role of antiplatelet therapy in peri-procedural outcomes needed investigation.
Purpose of the Study:
- To evaluate the impact of antiplatelet therapy on the initial success rate of PTCA.
- To assess the incidence of severe complications during PTCA in relation to antiplatelet use.
- To determine the effectiveness of different antiplatelet regimens.
Main Methods:
- Retrospective study of 179 patients undergoing PTCA.
- Comparison of initial success rates and complication incidence between patients with and without antiplatelet therapy.
- Analysis of outcomes based on specific antiplatelet agents (triflusal or aspirin plus dipyridamole).
Main Results:
- Overall initial PTCA success rate dropped to 70.4% without antiplatelet therapy, compared to 86.4% with it.
- Severe complications, primarily occlusion, occurred in 23.1% of patients without antiplatelet therapy versus 9.1% with it (P < 0.01).
- Success rates were similar for stable and unstable angina, but complications were significantly higher in the non-antiplatelet group.
Conclusions:
- Peri-angioplasty antiplatelet therapy is essential for improving PTCA success rates.
- Antiplatelet therapy significantly reduces the risk of severe periprocedural complications during PTCA.
- The findings support the routine use of antiplatelet agents in the peri-procedural period for patients undergoing PTCA.
Abstract:
In a retrospective study, during which 179 patients had undergone percutaneous transluminal coronary angioplasty (PTCA), the overall initial success rate fell suddenly and unexpectedly from more than 90% to 70.4%: 54.9% in patients not receiving antiplatelet therapy and 86.4% in patients treated orally with 300 mg triflusal three times daily or 300 mg acetylsalicylic acid plus 75 mg dipyridamole three times daily. The initial success rate was similar in patients with unstable (66.0%) and stable (77.6%) angina. The overall incidence of severe complications (mainly occlusion) was 16.2% and was significantly (P less than 0.01) greater in the patients not receiving antiplatelet therapy (23.1% versus 9.1%). There was no significant difference between incidence according to antiplatelet therapy used. It is concluded that antiplatelet therapy during the peri-angioplasty period (from 2 days before to 2 days after) may prevent periprocedural events in patients undergoing PTCA.